<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E02F474A-89FC-4013-9162-A69E12EEDF19"><gtr:id>E02F474A-89FC-4013-9162-A69E12EEDF19</gtr:id><gtr:name>NeuroTherapeutics Pharma, Inc. (NTP)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3CFB9490-9508-4E43-A019-042327F992A7"><gtr:id>3CFB9490-9508-4E43-A019-042327F992A7</gtr:id><gtr:name>Eisai Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Neuroscience Physiology and Pharmacology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E02F474A-89FC-4013-9162-A69E12EEDF19"><gtr:id>E02F474A-89FC-4013-9162-A69E12EEDF19</gtr:id><gtr:name>NeuroTherapeutics Pharma, Inc. (NTP)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3CFB9490-9508-4E43-A019-042327F992A7"><gtr:id>3CFB9490-9508-4E43-A019-042327F992A7</gtr:id><gtr:name>Eisai Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/78132E4B-F641-45DF-A5A9-D1CF2558D7C4"><gtr:id>78132E4B-F641-45DF-A5A9-D1CF2558D7C4</gtr:id><gtr:firstName>Trevor Graeme</gtr:firstName><gtr:surname>Smart</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4C521556-823A-457B-931F-424427AF13A0"><gtr:id>4C521556-823A-457B-931F-424427AF13A0</gtr:id><gtr:firstName>stephen</gtr:firstName><gtr:surname>Moss</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601529"><gtr:id>199EE397-F5EA-4F59-AD45-D1D05C4BEDBC</gtr:id><gtr:title>Regulating synaptic and extrasynaptic GABA-A receptors in health and disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601529</gtr:grantReference><gtr:abstractText>For the brain to function coherently, it is vital that individual nerve cells exert some control over their innate excitability. The main mechanism by which this is achieved involves the process of synaptic inhibition. Principally, this requires nerve cells to express GABA-A receptors at selected locations on their cell surface which are located opposite presynaptic nerve terminals releasing the neurotransmitter GABA. These structures are known as synapses. It is the release of GABA that activates the receptors causing a rapid but brief flow of chloride ions across the cell membrane through ion channels contained within the receptor structure. This flow either causes the cell to hyperpolarize, or massively increases the membrane conductance of the cell membrane, thereby reducing neuronal excitation. These receptors are known targets for numerous drugs, including, benzodiazepines, barbiturates, general anaesthetics and neurosteroids. A malfunction in synaptic inhibition, which could occur as a result of, a receptor mutation; a reduction in receptor numbers near GABA-releasing terminals; or because of dysregulation by naturally-occurring agents in the brain, can easily result in uncontrolled excitability with devastating consequences for humans, e.g., epilepsy. This research programme will focus on understanding the molecular mechanisms by which GABA-A receptors are regulated at or near synapses, and specifically what controls their movement (trafficking) into and out of synapses in the cell surface membrane. We will also concentrate on identifying which endogenous regulatory processes are important in modulating GABA-A receptor function and how they influence receptor trafficking. To this end, we have recently solved where a group of endogenous compounds in the brain, known as neurosteroids, bind to and modulate GABA-A receptors. With this knowledge we can use a genetic approach to dissect the importance of particular GABA-A receptor subtypes in health and disease processes. We plan to integrate our new knowledge into achieving a better understanding of how GABA-A receptors are regulated at synapses by studying synaptic plasticity: a phenomenon whereby synaptic transmission between neurones can be manipulated over time; and also by using animal models of disease, principally epilepsy. These aims will be achieved using cellular, genetic, molecular and pharmacological approaches in conjunction with novel techniques to explain how the most important inhibitory receptor in the brain controls nerve cell excitability. This study will be performed at UCL which is a recognised centre of excellence in neuroscience. The results of this research will be disseminated to the public via lectures and open publications</gtr:abstractText><gtr:technicalSummary>GABA-A receptors are vitally important for mediating synaptic inhibition in the CNS. This is emphasised not only by the consequences of their dysregulation, which is associated with neurological diseases, but also because they are targets for therapeutic agents. It is therefore important to understand those mechanisms that control the function and trafficking of GABA-A receptors at inhibitory synapses and extrasynaptic domains and how they ultimately shape synaptic inhibition. This work will build upon the foundations laid by our previous programme grant on the construction of inhibitory synapses. The main objectives will be addressed in four closely integrated sections: 

We will ascertain the important factors that determine the level and extent of lateral mobility for GABA-A receptors and why some receptor subtypes appear to be relatively static. We will study how new accessory proteins and their binding sites on receptor subunits influence receptor movement in addition to using electrophysiological methods to measure, in real time, GABA-A receptor movements between synapses and extrasynaptic domains. How endogenous modulators in the brain affect lateral receptor mobility will also be addressed.

The second section will build on our discovery of the neurosteroid binding sites on GABA-A receptors. We will establish the importance of these sites in other GABA-A receptor isoforms and deduce whether one or both binding sites needs to be occupied for modulation of GABA-A receptors. Lenti viral constructs will help us to decipher the role of receptor subtypes in mediating neurosteroid modulation and overall, their importance in health and disease will be addressed using two a subunit knock-ins generated by homologous recombination. 

In the third section, the mechanisms underlying inhibitory synaptic plasticity will be further investigated by studying the role of GABA-A receptor phosphorylation. We will establish how important surface trafficking mechanisms are for affecting long-term synaptic inhibition by changing receptor numbers at synaptic and extrasynaptic sites. New knock-in animals in which we have ablated selected phosphorylation sites will also be used to assess their impact on receptor trafficking and function.

The fourth aim will concentrate on understanding the importance of surface stability, subunit composition and mutations of GABA-A receptors in epilepsy using established animal models. This will include the association of GABA-A receptors with protein kinases and how this affects synaptic inhibition as well as the trafficking of GABA-A receptors.

Overall, this programme will provide insight into how neurones regulate their synaptic and extrasynaptic GABA-A receptors under physiological and pathophysiological conditions.</gtr:technicalSummary><gtr:fund><gtr:end>2013-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3179096</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Mechanism of action of THIP</gtr:description><gtr:id>3779DF71-163C-41C4-B491-5ECA600D737A</gtr:id><gtr:impact>We have deduced at the molecular level how THiP activates GABA receptors. This drug was developed as a hypnotic and reached phase II trials. We have a publication currently under revision</gtr:impact><gtr:outcomeId>B51A6F2D497-1</gtr:outcomeId><gtr:partnerContribution>Provision of resources to study the action of this hypnotic</gtr:partnerContribution><gtr:piContribution>We used multi-disciplinary approaches to exactly determine how THIP acts at the GABA-A receptor deriving new infomation about how GABA-A receptors are activated.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eisai Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Eisai London Research Laboratories</gtr:department><gtr:description>Neurodegeneration</gtr:description><gtr:id>2D8F49A9-2E87-4FA5-B92D-98FD52599BB5</gtr:id><gtr:impact>Impact of signalling pathways on neurodegenerative diseases.</gtr:impact><gtr:outcomeId>5FACE2C0FBE-1</gtr:outcomeId><gtr:piContribution>I am part of the Scientific Advisory Board for Eisai</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Down's syndrome and cognition</gtr:description><gtr:id>BA6C2E97-4CEF-4B28-9D2E-7EA45DE81130</gtr:id><gtr:impact>Analysing the strategy of treating Down's syndrome patients with GABA antagonists</gtr:impact><gtr:outcomeId>TYTwhwZqTkq-1</gtr:outcomeId><gtr:partnerContribution>Access to chemical leads and clinical trials design</gtr:partnerContribution><gtr:piContribution>Advising on the use of GABA atnagonists to improve cognition</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Trafficking of GABA-B receptors</gtr:description><gtr:id>AA7D8195-9531-4492-8589-3BA546B1A3AB</gtr:id><gtr:impact>We have one publication (PMID: 18812318) and several others will follow this collaboration at a later stage.</gtr:impact><gtr:outcomeId>45AE7E44951-1</gtr:outcomeId><gtr:partnerContribution>Developing novel methods to follow the movement of the G-protein coupled GABA-B receptor</gtr:partnerContribution><gtr:piContribution>We have developed a novel tracking method to follow the movement of the G-protein coupled GABA-B receptor in cell lines and neurones in real-time.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NeuroTherapeutics Pharma, Inc. (NTP)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Epilepsy treatment</gtr:description><gtr:id>68A4829E-CC90-413A-B248-CC45FDD03AFF</gtr:id><gtr:impact>agreed work plan as of Nov 2010 to investigate the site of action of the novel compound on GABA-A receptors</gtr:impact><gtr:outcomeId>aY3XKy9QFju-1</gtr:outcomeId><gtr:partnerContribution>Access to chemical lead structures</gtr:partnerContribution><gtr:piContribution>Advisor to Neurotherapeutics on the application of a novel drug to treat pain and epilepsy</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Croydon High School: Neuroscience</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2546A877-7837-4ACA-B42C-65D72B32E4A8</gtr:id><gtr:impact>Described the area of neuroscience to enthuse school children

Many sought careers advice</gtr:impact><gtr:outcomeId>MjyhHMh9Yg1</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Congress of Pharmacology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9AE63949-10D9-415B-A8DD-05F0EC238879</gtr:id><gtr:impact>&amp;gt;100 particpants

Latest developments in the glycine receptor field</gtr:impact><gtr:outcomeId>Rdxz2JBvQsG</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>9th Winter Brain Conference, Solden, Austria: Electrophysiological approaches to study membrane dynamics of GABAA receptors in the brain.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E609DFA9-73E9-44E3-B95C-2A42DFD81A09</gtr:id><gtr:impact>Plenary lecture

Recognition by peers</gtr:impact><gtr:outcomeId>8D7CED02A22</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scottish Neuroscience meeting: Plenary Keynote Lecture:</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>89C58486-ED38-4545-A4B6-937D5BBEC836</gtr:id><gtr:impact>Plenary keynote lecture

Recognition by peers</gtr:impact><gtr:outcomeId>F2A43C4F256</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GABA2010 conference, Venice: Plasticity of synaptic and extrasynaptic GABAA receptors</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BA8A544D-4539-4810-9F95-7480E4B24509</gtr:id><gtr:impact>Over 100 attended this talk on a basis for synaptic plasticity and what this means for health and disease in the nervous system

Asked to repeat this lecture in the UK and in Germany</gtr:impact><gtr:outcomeId>YrjXWqneDDa</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Rhine/Mainz/Max Planck plenary: Plasticity of synaptic and extrasynaptic inhibitory transmission</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>17D132A4-E8A6-4A4B-80DF-3F43F3385997</gtr:id><gtr:impact>Gave the firstt pleanery address to the first neuroscience meeting between Rhine and Mainz universitites together with Max-Planck

Excellent feedback from participants in terms of the coverage of novel technology and understanding of plasticity</gtr:impact><gtr:outcomeId>s2NoDCm1bRW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paris, CNRS: Molecular regulation of the GABAA receptor.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D34F2D82-E524-4D18-AE16-B1B075876B5A</gtr:id><gtr:impact>Lecture to academics &amp;amp; students

Recognition by peers, collaborative research links established</gtr:impact><gtr:outcomeId>DBBF7CA1F85</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCL Institute Structural and Molecular Biology retreat, Keynote lecture: Molecular regulation of the GABAA receptor.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0E8E852C-0917-4960-AC53-F8B8AF39CAD2</gtr:id><gtr:impact>Plenary lecture

none so far</gtr:impact><gtr:outcomeId>0B2B4A9C8D2</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kyoto symposium on Mechanisms of GABAergic Synaptic Transmission, Japanese Neuroscience Society meeting. Autocrine mGluR1 activation in cerebellar Purkinje cells regulates GABA-mediated synaptic inhibition.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8B70DE9D-943B-4EEE-90BD-5826B77C645C</gtr:id><gtr:impact>Plenary lecture

Representing UK neuroscience</gtr:impact><gtr:outcomeId>B1BE0ADC0E5</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Max Planck symposium Ringberg Castle, Munich: Intercellular communication in the nervous system, from development to roles in health and disease. Keynote Lecture: Structure-function studies on inhibitory amino acid receptors.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6DE9BA46-6947-4F79-B0C1-5607F3402BF3</gtr:id><gtr:impact>Keynote lecture

none so far</gtr:impact><gtr:outcomeId>767C5F5F75D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>9th Winter Brain Conference, Solden, Austria: Electrophysiological approaches to study membrane dynamics of GABAA receptors in the brain.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>70FAF0BF-195F-4805-A86A-F98B8A46E1C8</gtr:id><gtr:impact>Research seminar to academics

None so far</gtr:impact><gtr:outcomeId>960F96AAA83</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Clinical Sciences Centre, Imperial College London:</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>83DED293-CE74-4023-B792-F1008A5B4BAC</gtr:id><gtr:impact>Lecture to academics &amp;amp; students

Highlighting pharmacological approaches to CNS study</gtr:impact><gtr:outcomeId>5997AF1F147</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gaddum Medal Address</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E0F1CC69-4295-4B7E-B460-F6425922E3F1</gtr:id><gtr:impact>Summary if the field

Advancement of Pharmacology</gtr:impact><gtr:outcomeId>J4G6wEGV1Ff</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pewterer's Lecture Award</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F74B3B80-8B87-4D88-AD3F-359594312BBD</gtr:id><gtr:impact>Lecture to public and professionals

Funding for Fellowships</gtr:impact><gtr:outcomeId>P86nUxyVtYF</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Eisai, UCL. The Inhibitory Synapse.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AA78CC38-669F-4430-A357-14E22CE347F9</gtr:id><gtr:impact>Seminar to acadmics &amp;amp; industrialists

Part of Eisai scientific advisory board</gtr:impact><gtr:outcomeId>7169EB40371</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Distinguished Gowdey Lecture</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>27692461-587E-4FAA-A596-11A745E5F88D</gtr:id><gtr:impact>Prize lecture on GABA-A receptors, basic science and clinical

Recognition by peers</gtr:impact><gtr:outcomeId>612FFD71129</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Max Planck symposium Ringberg Castle, Munich: Intercellular communication in the nervous system, from development to roles in health and disease. Keynote Lecture: Structure-function studies on inhibitory amino acid receptors.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>58C7083A-05C1-450A-9F86-8BA8392E1DCA</gtr:id><gtr:impact>Plenary lecture

Recognition by peers</gtr:impact><gtr:outcomeId>24DF5D088E4</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCL Institute Structural and Molecular Biology retreat, Keynote lecture: Molecular regulation of the GABAA receptor.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>724A26C9-87CD-4849-989C-0325473642D2</gtr:id><gtr:impact>Plenary lecture

Recognition by peers</gtr:impact><gtr:outcomeId>29C889057ED</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>557031</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Research Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>583479BB-1103-4E99-B6B9-3A0D6D6EF872</gtr:id><gtr:outcomeId>FE00DFFDE000</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>327468</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EU FP7</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>752409DF-C0F6-4ED8-A446-AAB7F964F410</gtr:id><gtr:outcomeId>ECB5AF9A3D00</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G9722520</gtr:fundingRef><gtr:id>B5C6A105-4EA0-4B73-9305-5B1436F40077</gtr:id><gtr:outcomeId>168466754880</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>830000</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Swiss National Science Foundation project grant</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Swiss National Science Foundation</gtr:fundingOrg><gtr:id>29B74559-FAE3-4A79-ADEB-F782FA9C062B</gtr:id><gtr:outcomeId>htj2jmnce6n0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We discovered two neurosteroid binding sites on the GABA-A receptor which have been long sought after for over 25 years.</gtr:description><gtr:grantRef>G0601529</gtr:grantRef><gtr:id>43CA5CFC-D0D7-4F9B-91DD-356FDA46A405</gtr:id><gtr:impact>Interest from Pharmaceutical companies who wish to target this novel site for therapeutic development in the treatment of anxiety and epilepsy.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>28D262C4ED4</gtr:outcomeId><gtr:patentId>WO2006075187</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Neurosteroid binding site on the GABA-A receptor</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>MRC funded work, currently trying to devise a method for enabling this drug to pass through the blood brain barrier</gtr:description><gtr:id>1D1214CE-466C-457F-A07C-578375175BD0</gtr:id><gtr:impact>Development process clearly indicates this is a potentially viable route for the treatment of absence epilepsy.</gtr:impact><gtr:outcomeId>pidyzGoM8rm</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Partial agonist for absence epilepsy</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Photoactive compounds capable of irreversibly modifying the function of GABA receptors</gtr:description><gtr:id>63EE5E21-C031-42C1-BD5F-A7E7BC86FD02</gtr:id><gtr:impact>Potential appication in epilepsy and cognition. Compounds allow tracking of natvie GABA receptors in real time.</gtr:impact><gtr:outcomeId>h1HoA4mSxTs</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Photoactive chemical probes</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New mechanism of synaptic plasticity at inhibitory synapses involving the retrograde release of glutamate and defined by new materials.</gtr:description><gtr:id>BC6D9509-AC77-4AFE-9042-CE3E94769F49</gtr:id><gtr:impact>Re-assessment as to how the strength of synaptic inhibition is controlled. Likely to have significant impact on synaptic physiology</gtr:impact><gtr:outcomeId>43B543CD686</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Defining presynaptic inhibitory plasticity</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New antiboides that recognise GABA-A receptor phosphorylation status</gtr:description><gtr:id>6FA7B12E-D8AB-4183-AB3F-5D075D4B3D33</gtr:id><gtr:impact>Ability to recognise when receptors are phosphorylated without using P32 measurements.</gtr:impact><gtr:outcomeId>483E3F09A3F</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Phospho-specific antibodies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New method for functionally following the trafficking of lignad-gated ion channels in cell membranes</gtr:description><gtr:id>EBC30B99-A685-4D49-A3F7-691B21652DD1</gtr:id><gtr:impact>Ability to use live (neurones) cells and unequivocally follow the trafficking of synaptic receptors</gtr:impact><gtr:outcomeId>0A794C30F84</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Tracking GABA-A receptors</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New chemical structures capable of irreversibly binding to the GABA receptor and modulating its function</gtr:description><gtr:id>D9ADBC11-44EB-4834-9859-D5135FF018C7</gtr:id><gtr:impact>Will allow specfic tracking of native GABA receptors and may prove useful in moderating the level of synaptic and tonic inhibition that could prove useful in epilepsy and/or cognition.</gtr:impact><gtr:outcomeId>C4TNE5ga3UM</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Photoactive GABA ligands</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3B40C663-10DF-42A6-BCB5-9110C1D86801</gtr:id><gtr:title>Sushi domains confer distinct trafficking profiles on GABAB receptors.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b73c51219133dc391ce8829da2883a79"><gtr:id>b73c51219133dc391ce8829da2883a79</gtr:id><gtr:otherNames>Hannan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_14675_25_22778417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01607F58-8D74-4A07-81A6-351CD6A51DB3</gtr:id><gtr:title>Distinct activities of GABA agonists at synaptic- and extrasynaptic-type GABAA receptors.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30373c619109bc39028647979ba3b159"><gtr:id>30373c619109bc39028647979ba3b159</gtr:id><gtr:otherNames>Mortensen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>HJX5MVthPU3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A36EDC2-7F2A-40D7-87C2-889AF33E48A9</gtr:id><gtr:title>Ubiquitin-dependent lysosomal targeting of GABA(A) receptors regulates neuronal inhibition.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c7ca64b87eec214d6deaec9a39a152d"><gtr:id>6c7ca64b87eec214d6deaec9a39a152d</gtr:id><gtr:otherNames>Arancibia-C?rcamo IL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>488CEC58C73</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5588C4C9-02B4-45F2-B3C0-E1B7C3FB00D5</gtr:id><gtr:title>Prolonged activation of NMDA receptors promotes dephosphorylation and alters postendocytic sorting of GABAB receptors.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d0e6628deeb5c98efa876e7b3da27ea"><gtr:id>1d0e6628deeb5c98efa876e7b3da27ea</gtr:id><gtr:otherNames>Terunuma M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>B3ZrS9aYKSz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>596BEB79-DC42-4FFF-A656-79EB42CA2B6D</gtr:id><gtr:title>Method for estimating the tip geometry of scanning ion conductance microscope pipets.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc338f319835d64b7b592c855897b862"><gtr:id>cc338f319835d64b7b592c855897b862</gtr:id><gtr:otherNames>Caldwell M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>5460e8cf274812.56593256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>036E1A33-6A02-4304-9315-C67B9CCFB8AC</gtr:id><gtr:title>Handling accumulated internal Cl- at inhibitory synapses.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e568ab1412fca1c4dc62cb3bcfae9c6c"><gtr:id>e568ab1412fca1c4dc62cb3bcfae9c6c</gtr:id><gtr:otherNames>Smart TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>g9t4utzESku</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70B844DE-9D38-4D20-A65F-E52D237A0871</gtr:id><gtr:title>CaMK-II modulation of GABA(A) receptors expressed in HEK293, NG108-15 and rat cerebellar granule neurons.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3edee91a0b5b4fed9a9168a8023d780d"><gtr:id>3edee91a0b5b4fed9a9168a8023d780d</gtr:id><gtr:otherNames>Houston CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>511F784B11C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A04AD85-C61B-4F36-BE0D-DAACF5DB2B0C</gtr:id><gtr:title>Use of electrophysiological methods in the study of recombinant and native neuronal ligand-gated ion channels.</gtr:title><gtr:parentPublicationTitle>Current protocols in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a743390220adf77fab7bcb8de2d5452"><gtr:id>4a743390220adf77fab7bcb8de2d5452</gtr:id><gtr:otherNames>Thomas P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1934-8282</gtr:issn><gtr:outcomeId>5460e8cf5462f8.79057749</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD312A2E-548D-456E-866C-0158CBB511CE</gtr:id><gtr:title>Tracking cell surface GABAB receptors using an alpha-bungarotoxin tag.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed0fd074168237c1eedafa78e4dc1a0c"><gtr:id>ed0fd074168237c1eedafa78e4dc1a0c</gtr:id><gtr:otherNames>Wilkins ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>F5A52DD00AC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0092A0A0-C236-4784-8A01-3283C6238E5C</gtr:id><gtr:title>GABA and glycine as neurotransmitters: a brief history.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51d6c91c012651953124e3cc901df163"><gtr:id>51d6c91c012651953124e3cc901df163</gtr:id><gtr:otherNames>Bowery NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>FFF6609D19D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CD6DAE0-B166-41A9-83E1-C4E6787625B3</gtr:id><gtr:title>Neurosteroid binding sites on GABA(A) receptors.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5e4d4bbaa4bb84366fdf7f821f614f1"><gtr:id>f5e4d4bbaa4bb84366fdf7f821f614f1</gtr:id><gtr:otherNames>Hosie AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>EAAAD8CDFC7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6808FA99-6D1F-4AAE-A4EB-851A27448121</gtr:id><gtr:title>Gamma-aminobutyric acid type B (GABA(B)) receptor internalization is regulated by the R2 subunit.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b73c51219133dc391ce8829da2883a79"><gtr:id>b73c51219133dc391ce8829da2883a79</gtr:id><gtr:otherNames>Hannan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>X81rRsKd4pP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B304776A-7C31-41A0-9AB6-D81A0233AF45</gtr:id><gtr:title>Deficits in spatial memory correlate with modified {gamma}-aminobutyric acid type A receptor tyrosine phosphorylation in the hippocampus.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cd998cdbfc2b7a4f7a07a4be24319c5"><gtr:id>0cd998cdbfc2b7a4f7a07a4be24319c5</gtr:id><gtr:otherNames>Tretter V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>C62AB1B6B38</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24EF4B38-ADCE-4B34-915F-1D8E3606DB3B</gtr:id><gtr:title>Dynamic mobility of functional GABAA receptors at inhibitory synapses.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a743390220adf77fab7bcb8de2d5452"><gtr:id>4a743390220adf77fab7bcb8de2d5452</gtr:id><gtr:otherNames>Thomas P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>E896E44A63C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AEEA7C3-1002-4EDB-8989-D43B7159F77E</gtr:id><gtr:title>Nanoscale live-cell imaging using hopping probe ion conductance microscopy.</gtr:title><gtr:parentPublicationTitle>Nature methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5c74f2f031a8194794fe50f22d63d5c"><gtr:id>f5c74f2f031a8194794fe50f22d63d5c</gtr:id><gtr:otherNames>Novak P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1548-7091</gtr:issn><gtr:outcomeId>0BD69EF37C0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71CDCE4D-3283-44FA-8231-D6E3CC4B1A2E</gtr:id><gtr:title>Distinct regulation of beta2 and beta3 subunit-containing cerebellar synaptic GABAA receptors by calcium/calmodulin-dependent protein kinase II.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3edee91a0b5b4fed9a9168a8023d780d"><gtr:id>3edee91a0b5b4fed9a9168a8023d780d</gtr:id><gtr:otherNames>Houston CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>5FA88A059DE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3149BD95-D883-486E-8D4D-FCF503F76C94</gtr:id><gtr:title>Binding, activation and modulation of Cys-loop receptors.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5d4baceaf0e34aa81cd387370317059"><gtr:id>e5d4baceaf0e34aa81cd387370317059</gtr:id><gtr:otherNames>Miller PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>XRL4AYzyr7Y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB1AB582-B895-4BAF-B725-700BF669E03F</gtr:id><gtr:title>Benzodiazepines modulate GABAA receptors by regulating the preactivation step after GABA binding.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b291b4d4a141fc5383ef192c2f960af1"><gtr:id>b291b4d4a141fc5383ef192c2f960af1</gtr:id><gtr:otherNames>Gielen MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>pm_14675_25_22539833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D13DD95-8793-4F51-B163-DE03E6601387</gtr:id><gtr:title>The future of pharmacology.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c16d76ec09e437bccd897d8a130a58a"><gtr:id>4c16d76ec09e437bccd897d8a130a58a</gtr:id><gtr:otherNames>Vallance P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>89E383B7BC5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BABDD1FA-DF8B-4919-B6E3-C9ED81846B57</gtr:id><gtr:title>Mapping a molecular link between allosteric inhibition and activation of the glycine receptor.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5d4baceaf0e34aa81cd387370317059"><gtr:id>e5d4baceaf0e34aa81cd387370317059</gtr:id><gtr:otherNames>Miller PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>C03E7F12E62</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42281845-C3FC-4616-ACA4-7822251131EC</gtr:id><gtr:title>Synthesis and evaluation of highly potent GABA(A) receptor antagonists based on gabazine (SR-95531).</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48685c1a8a7d1e2ebcb720993c9bd61b"><gtr:id>48685c1a8a7d1e2ebcb720993c9bd61b</gtr:id><gtr:otherNames>Iqbal F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>DoZFnFz87gS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8A32AA9-46D5-469D-9B3F-BB574FBFF544</gtr:id><gtr:title>Somatodendritic release of glutamate regulates synaptic inhibition in cerebellar Purkinje cells via autocrine mGluR1 activation.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23288a146ff577acc03a03ddcc9c89bd"><gtr:id>23288a146ff577acc03a03ddcc9c89bd</gtr:id><gtr:otherNames>Duguid IC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>B4EB344925D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>596BC8E8-C929-4BDA-8320-58F6617E51F0</gtr:id><gtr:title>Conserved site for neurosteroid modulation of GABA A receptors.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5e4d4bbaa4bb84366fdf7f821f614f1"><gtr:id>f5e4d4bbaa4bb84366fdf7f821f614f1</gtr:id><gtr:otherNames>Hosie AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>D46BD27A88A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11DF912C-2356-4507-8D0D-B84E6D097C2E</gtr:id><gtr:title>Single-channel recording of ligand-gated ion channels.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30373c619109bc39028647979ba3b159"><gtr:id>30373c619109bc39028647979ba3b159</gtr:id><gtr:otherNames>Mortensen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn><gtr:outcomeId>A4B29BB2829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEC6E1F1-455A-4B2E-A7F0-8C853B1B7697</gtr:id><gtr:title>Extrasynaptic alphabeta subunit GABAA receptors on rat hippocampal pyramidal neurons.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30373c619109bc39028647979ba3b159"><gtr:id>30373c619109bc39028647979ba3b159</gtr:id><gtr:otherNames>Mortensen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>E22466F58F7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE7B337C-C306-43B6-AE76-1A3F48A933BD</gtr:id><gtr:title>Phospho-dependent functional modulation of GABA(B) receptors by the metabolic sensor AMP-dependent protein kinase.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85657eed46ae4566f7a1bb52a6fd0a2b"><gtr:id>85657eed46ae4566f7a1bb52a6fd0a2b</gtr:id><gtr:otherNames>Kuramoto N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>E155A1AC6DF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A9666D4-BD96-42CE-9986-08DF49C8A39A</gtr:id><gtr:title>The major central endocannabinoid directly acts at GABA(A) receptors.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b6e27d279139b5461a57595d567f0f1"><gtr:id>1b6e27d279139b5461a57595d567f0f1</gtr:id><gtr:otherNames>Sigel E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>LtZR8QXe835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4B20E0F-9390-412E-819E-2638778CCAE6</gtr:id><gtr:title>CaMKII phosphorylation of the GABA(A) receptor: receptor subtype- and synapse-specific modulation.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3edee91a0b5b4fed9a9168a8023d780d"><gtr:id>3edee91a0b5b4fed9a9168a8023d780d</gtr:id><gtr:otherNames>Houston CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>44C935B95AC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9436541A-5281-4AEC-959C-062C08BE8E70</gtr:id><gtr:title>Serotonin receptor 1A-modulated phosphorylation of glycine receptor a3 controls breathing in mice.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af30ff65d6024f13feb378ec432b34be"><gtr:id>af30ff65d6024f13feb378ec432b34be</gtr:id><gtr:otherNames>Manzke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>U6UQsULSjDw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D669559F-67AE-4462-9AFC-3AEC15E64A31</gtr:id><gtr:title>Intracellular chloride ions regulate the time course of GABA-mediated inhibitory synaptic transmission.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3edee91a0b5b4fed9a9168a8023d780d"><gtr:id>3edee91a0b5b4fed9a9168a8023d780d</gtr:id><gtr:otherNames>Houston CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>B787269CC32</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22CE6E2C-BFD6-44B8-A08D-E42DEA240960</gtr:id><gtr:title>Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5e4d4bbaa4bb84366fdf7f821f614f1"><gtr:id>f5e4d4bbaa4bb84366fdf7f821f614f1</gtr:id><gtr:otherNames>Hosie AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>EB0F5080A50</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E8BDCFC-1672-44F3-B91B-439BD6E1F9A4</gtr:id><gtr:title>Identification of the sites for CaMK-II-dependent phosphorylation of GABA(A) receptors.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3edee91a0b5b4fed9a9168a8023d780d"><gtr:id>3edee91a0b5b4fed9a9168a8023d780d</gtr:id><gtr:otherNames>Houston CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>AA105994A54</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601529</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>